Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab

被引:62
作者
Torii, Hideshi [1 ]
Sato, Noriko [3 ]
Yoshinari, Toru [3 ]
Nakagawa, Hidemi [2 ]
机构
[1] Social Insurance Cent Gen Hosp Tokyo, Div Dermatol, Tokyo, Japan
[2] Jikei Univ, Sch Med, Dept Dermatol, Tokyo, Japan
[3] Mitsubishi Tanabe Pharma, Osaka, Japan
关键词
Dermatology Life Quality Index of 0 or 1; infliximab; psoriasis; Psoriasis Area and Severity Index 90; treatment goal; PLACEBO-CONTROLLED TRIAL; PLAQUE-TYPE PSORIASIS; RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; EFFICACY; METHOTREXATE; MULTICENTER; INDUCTION; THERAPY;
D O I
10.1111/j.1346-8138.2011.01459.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
European S3 Guidelines on the systemic treatment of psoriasis in 2009 propose 75% or more improvement in the Psoriasis Area and Severity Index from baseline (PASI 75) and a Dermatology Life Quality Index (DLQI) of 0 or 1 as treatment goals. However, the relationship of these two parameters is yet to be clarified. Herein, we analyzed the data pooled from two Japanese phase III clinical trials on psoriasis with infliximab to clarify the PASI response necessary to achieve a DLQI of 0 or 1. Of the 90 patients, the mean percent improvement in PASI at week 50 or 66 was 74.5%, and the PASI 75 and PASI 90 response rates were 66.7% and 46.7%, respectively; no difference in the improvement was noted among the body areas. Significant improvements in nail psoriasis were also observed. A negative correlation was shown between the improvement in PASI and DLQI. Patients who achieved a PASI 90 response had a significantly higher percentage of achieving a DLQI of 0 or 1 than the patients who achieved a PASI 75 but not a PASI 90 response. The median serum trough level of infliximab was maintained at 2 mu g/mL or more in the PASI 90 responders, whereas it was less than 1 mu g/mL at week 30 and on in the others. The present results demonstrate that a PASI 90 response is necessary to achieve a DLQI of 0 or 1. Infliximab is considered a useful drug in meeting the treatment goal of achieving a DLQI of 0 or 1 through the attainment of a PASI 90 response.
引用
收藏
页码:253 / 259
页数:7
相关论文
共 21 条
  • [1] Disease severity, quality of life and health care in plaque-type psoriasis:: A multicenter cross-sectional study in Germany
    Augustin, M.
    Krueger, K.
    Radtke, M. A.
    Schwippl, I.
    Reich, K.
    [J]. DERMATOLOGY, 2008, 216 (04) : 366 - 372
  • [2] The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    Clair, EWS
    Wagner, CL
    Fasanmade, AA
    Wang, B
    Schaible, T
    Kavanaugh, A
    Keystone, EC
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (06): : 1451 - 1459
  • [3] Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
    Gottlieb, AB
    Evans, R
    Li, S
    Dooley, LT
    Guzzo, CA
    Baker, D
    Bala, M
    Marano, CW
    Menter, A
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (04) : 534 - 542
  • [4] Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease
    Hibi, Toshifumi
    Sakuraba, Atsushi
    Watanabe, Mamoru
    Motoya, Satoshi
    Ito, Hiroaki
    Motegi, Kenta
    Kinouchi, Yoshitaka
    Takazoe, Masakazu
    Suzuki, Yasuo
    Matsumoto, Takayuki
    Kawakami, Kazuhiko
    Matsumoto, Takayuki
    Hirata, Ichiro
    Tanaka, Shinji
    Ashida, Toshifumi
    Matsui, Toshiyuki
    [J]. INFLAMMATORY BOWEL DISEASES, 2012, 18 (08) : 1480 - 1487
  • [5] The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis
    Katugampola, R. P.
    Lewis, V. J.
    Finlay, A. Y.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (05) : 945 - 950
  • [6] The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis A Population-Based Cohort Study
    Kurd, Shanu Kohli
    Troxel, Andrea B.
    Crits-Christoph, Paul
    Gelfand, Joel M.
    [J]. ARCHIVES OF DERMATOLOGY, 2010, 146 (08) : 891 - 895
  • [7] Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO
  • [8] 2-W
  • [9] Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
    Maser, Elana A.
    Villela, Renata
    Silverberg, Mark S.
    Greenberg, Gordon R.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (10) : 1248 - 1254
  • [10] Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    Papp, Kim A.
    Langley, Richard G.
    Lebwohl, Mark
    Krueger, Gerald G.
    Szapary, Philippe
    Yeilding, Newman
    Guzzo, Cynthia
    Hsu, Ming-Chun
    Wang, Yuhua
    Li, Shu
    Dooley, Lisa T.
    Reich, Kristian
    [J]. LANCET, 2008, 371 (9625) : 1675 - 1684